Response To: Chiari Malformation Type 0: Methodological Concerns Regarding the Null Structural Finding - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Reply to: Methodological Issues in the Structural Analysis of Chiari Malformation Type 0

  • By

  • B. Candan

  • B. Ozkal

  • E. Top

  • August 15, 2026

Share

Original Source(s)

Response To: Chiari Malformation Type 0: Methodological Concerns Regarding the Null Structural Finding

  • by B. Candan, B. Ozkal, E. Top

  • August 15, 2026

Related Content

Errors in Methods and Supplement 1

  • August 1, 2026

Can SGLT2 Inhibitors Affect Dementia?

A target trial emulation using Veterans Affairs electronic health records examined neuropsychiatric outcomes associated with SGLT2 inhibitor use.

FDA approves tau PET imaging agent

The F18-labeled agent is indicated for brain PET imaging to identify tau neurofibrillary tangle pathology.